Abstract
antibody responses against all four DENV serotypes as there is no concern for replication 87 interference, which is a key issue for a live attenuated dengue vaccine (14).
88
It has been reported that the co-expression of flavivirus precursor membrane (prM) and 
Results

98
Amino acid mutation in E produces DENV1 VLP at high yield.
99
The DENV genome encodes three structural proteins (capsid; C, prM and E) that form the virus 100 coat, and seven non-structural proteins that take part in virus replication within host cells. The 101 complex of prM and E plays important roles in virus assembly and fusion to the host cell 102 membrane. The E protein lies on the surface of the dengue virion and plays a direct role in cell 103 entry, thus recognized as a target for dengue vaccine development (22). We created an 104 expression plasmid DENV1 prM-E, containing the hydrophobic signal sequence (ss, located 105 between C and prM), prM, and E genes of DENV1 (Fig. 1A) . When transfected into 293F cells, the supernatant was very low as measured by western blotting using anti-DENV1-4 E 108 monoclonal antibody (Fig. 1B , middle lane).
109
To overcome the low yield, we focused on modifying DENV E for the following reasons:
110 DENV E protein undergoes structural conformational changes when the dengue virion fuses with 111 the host cell membrane. In a previously reported work on alphavirus VLP vaccine development,
112
it was shown that mutating E2 protein in the region of the conformational change greatly (24), we hypothesized that a modification to the amino acid(s)
115
which impacts E protein conformational change may also increase DENV VLP yield. We 116 selected 27 amino acids that could potentially impact the conformational change of the DENV1
117
E protein, introduced a single amino acid mutation for each residue, and assessed VLP 118 production levels in the culture supernatant (Table 1) . As a result, we found that the substitution 119 of phenylalanine 108 to alanine (F108A) greatly increased the DENV1 VLP production. The 120 production of DENV1 prM-E F108A VLP (hereafter called DENV1 VLP) was about 16-fold higher 121 than wild-type DENV1 prM-E (Fig. 1B) .
123
Development of DENV2, DENV3, DENV4, and ZIKV VLPs. 124 F108 is located in the fusion loop structure of DENV E protein, which consists of hydrophobic 125 amino acids and is responsible for the insertion of DENV E protein into the host cell membrane 126 (22). As this sequence is highly conserved among flaviviruses, we expected that the F108A 127 mutation would also increase the production of other serotypes of DENV VLPs. Hence, we first 128 constructed expression plasmids encoding DENV2 prM-E with or without the F108A mutation
129
( Fig. 2A, DENV2 prM-E F108A and prM-E). However, when transfected into 293F cells, DENV2
prM-E or prM-E F108A did not secrete VLPs into the culture supernatant as measured by western 131 blotting using anti-DENV2 E polyclonal antibody (Fig. 2B) DENV2 VLP result, the production of DENV4 VLP with F108A mutation and EDIII and ST/TM 149 replacement (prM-E F108A _4/1) was about 14-fold higher than that of the VLP without F108 150 mutation (prM-E 4/1) (Fig. 3B ).
151
We also tested this strategy to develop Zika virus (ZIKV) VLP. ZIKV is another 152 mosquito-borne flavivirus responsible for the recent outbreaks in South and Central America (26), and its structure is similar to that of other flaviviruses including DENV (27 mutation may be applied to increase flavivirus VLP production.
164
Production and characterization of DENV1-4 VLPs.
165
The production levels of DENV2 and 4 VLP were relatively lower than that of DENV3 VLP.
166
The original DENV2 expression constructs tested in Fig. 2 
Discussion
257
The global spread and persistence of DENV has made dengue vaccine development a pressing 258 matter. In this study, we found an effective strategy to produce DENV VLPs and developed a 259 novel tetravalent dengue VLP vaccine which induces strong neutralizing responses against all 260 four DENV serotypes.
261
The introduction of an F108A mutation in E protein increased VLP production in all four 262 serotypes of DENV as well as ZIKV. Amino acid residue F108 is located in the fusion loop of E 263 which is highly conserved among flaviviruses (37). During viral infection, the E protein 264 undergoes conformational changes that exposes the hydrophobic fusion loop on the viral surface.
265
The fusion loop is inserted into the host cell membrane and induces fusion of the viral and host the production process, thereby leading to the high-level VLP production observed.
271
For DENV2-4, in addition to the F108A mutation, the replacement of C-terminal region
272
with that of the corresponding region of DENV1 was necessary to achieve efficient VLP phama Biomedical) for 1 h at room temperature and washed with PBS-0.05% Tween-20 (PBS-T).
415
The test sera and standard control were diluted at 1:1,000 and were added to wells, incubated for 
459
Infection enhancement (measured as ADE activity) was tested using serum samples that was Right: Western blot analysis of the ZIKV VLP constructs. Culture supernatant was harvested at 4 521 days post-transfection and E proteins were detected by rabbit anti-ZIKV E polyclonal antibody.
Representative images from at 3 independent experiments are shown. comparisons test, where ***; P < 0.001. **; P < 0.01, *; P < 0.05, ns; not significant. Western blot analysis of DENV1 VLP-containing culture supernatant. 293F cells were transfected with control vector or expression plasmids encoding wild type DENV1 prM-E (prM-E) or prM-E with F108A mutation (prM-E F108A ), and cultured for 4 days. Secreted DENV1 VLP was detected using a mouse anti-dengue1-4 E monoclonal antibody. The intensities for each band were measured and the relative intensity was calculated by setting the intensity of prM-E as 1.0. A representative image from at least 3 independent experiments is shown. prM-E; wild type sequence of DENV2 prM-E, prM-E F108A ; prM-E with F108A mutation, chimera 1-4: Chimeric DENV2 E constructs that have F108A mutation and different length of DENV1 E at C-terminal region. prM-E_2/1; DENV2 E protein aa.297-495 region was substituted with corresponding region of DENV1 E protein, prM-E F108A _2/1: prM-E_2/1 with F108A mutation. EDIII: envelope domain III, ST/TM; stem and transmembrane anchor. (B, C) Western blot analysis of the DENV2 VLPs in the culture supernatant. Expression vectors were transfected into 293F cells and culture supernatant were tested for VLP production on day 4 by using goat anti-DENV2 E polyclonal antibody. Representative images from at least 3 independent experiments are shown. (B) Effects of F108A mutation in prM-E or prM-E_2/1. The intensities for each band were measured and the relative intensity was calculated by setting the intensity of comparing prM-E_2/1 as 1.0. (C) Effects of substituting length of DENV2 C-terminal region on VLP production. 
FIG 7
Immunogenicity and neutralizing activity of tetravalent DNA or VLP vaccines. 6-week-old female BALB/c mice (n=4) were immunized with 80 µg (20 µg of each serotype) of tetravalent DNA or tetravalent DENV VLP three times at 3-week intervals. DNAs were immunized by intramuscular injection and electroporation, VLPs were immunized by regular intramuscular injection with Alum. Serum was collected two weeks after the last immunization. DNA_wild type: DENV1-4 prM-E encoding plasmids, DNA_F108A: DENV1-4 VLP encoding plasmids, VLP: purified DENV1-4 VLPs. (A) Serum anti-flavivirus IgG titer was determined by ELISA. Mean log10 ELISA titers (mean ± SD) are shown. One-way ANOVA followed by Tukey's multiple comparisons test, where *; P < 0.05. (B) Serum neutralization titers against DENV1-4. Each symbol represents the FRNT 50 titer from an individual mouse, and the geometric mean titers are represented by horizontal bars. One-way ANOVA followed by Tukey's multiple comparisons test, where ***; P < 0.001. **; P < 0.01, *; P < 0.05, ns; not significant. 
TABLE 1
VLP secretion of DENV1 prM-E mutants into culture supernatant. DENV1 VLP was detected using mouse anti-dengue1-4 E monoclonal antibody. The intensities for each band were measured and the relative intensity was calculated by setting the intensity of wild type DENV1 prM-E was 1.0.
-: no DENV1 VLP was detected in culture supernatant by Western Blotting with using anti-DENV E antibody. + : equal or less than 1 fold , ++ : 1.1 to 3 fold, +++: more than 3 fold VLP production compared to wild-type DENV1 prM-E.
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